CLINICAL TRIALS PROFILE FOR AVONEX
✉ Email this page to a colleague
All Clinical Trials for AVONEX
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00001785 ↗ | Recombinant Human Interferon Beta-1a (Avonex) for the Treatment of Patients With HTLV-1-Associated Myelopathy (HAM) | Completed | National Institute of Neurological Disorders and Stroke (NINDS) | Phase 2 | 1998-09-01 | HTLV stands for human T cell leukemia virus. HTLV-1 is a virus that attacks specific kinds of white blood cells called T cells. T cells are part of the natural defense system of the body. HTLV-1 has been associated with leukemia and lymphoma. In addition, approximately 1% of all patients infected with HTLV-1 develops a condition known as HTLV-1 associated myelopathy (HAM) / tropical spastic paraparesis (TSP). Currently there is no clearly defined, effective treatment for patients with HAM/TSP. Steroids have been used as therapy but have only been able to provide temporary relief of symptoms. Human interferon is a small protein released from different kinds of cells in the body. Interferon has been known to have antiviral and immunological effects and has been used to treat hepatitis and multiple sclerosis. Interferon Beta is released from cells called fibroblasts. These cells play a role in the production of connective tissue. The purpose of this study is to evaluate the possible role of recombinant interferon beta (Avonex) in treatment of HAM/TSP. The study is broken into three phases, a pre-treatment phase, a treatment phase, and a post-treatment phase. The total duration of the study will be 44 weeks. Patients participating in this study will receive injections of Avonex 1 to 2 times a week. Throughout the study patients will regularly submit blood samples and undergo diagnostic tests such as MRI and measures of somatosensory evoked potentials. |
| NCT00030966 ↗ | Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis | Completed | Elan Pharmaceuticals | Phase 3 | 2002-01-01 | The purpose of this study is to determine if natalizumab in combination with AVONEX is safe and effective in delaying progression of individuals diagnosed with relapsing remitting Multiple Sclerosis (MS). |
| NCT00030966 ↗ | Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis | Completed | Biogen | Phase 3 | 2002-01-01 | The purpose of this study is to determine if natalizumab in combination with AVONEX is safe and effective in delaying progression of individuals diagnosed with relapsing remitting Multiple Sclerosis (MS). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for AVONEX
Condition Name
Clinical Trial Locations for AVONEX
Trials by Country
Clinical Trial Progress for AVONEX
Clinical Trial Phase
Clinical Trial Sponsors for AVONEX
Sponsor Name
